Ola Vedin

Boehringer Ingelheim, Binger Str. 173
Ingelheim Am Rhein, RP 55216, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.

Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Journal of the American Society of Nephrology : JASN

Published: July 07, 2025

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial.

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial.

Journal: Cardiovascular diabetology

Published: March 07, 2024

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.

Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 13, 2023

"Click and mortar" opportunities for digitization and consumerism in trials.

"Click and mortar" opportunities for digitization and consumerism in trials.

Journal: Contemporary clinical trials

Published: March 02, 2023

Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.

Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.

Journal: Journal of cardiac failure

Published: February 10, 2023

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.

Journal: Journal of the American Heart Association

Published: December 24, 2022

Health status across major subgroups of patients with heart failure and preserved ejection fraction.

Health status across major subgroups of patients with heart failure and preserved ejection fraction.

Journal: European journal of heart failure

Published: October 21, 2022

Patients With Bicuspid Aortic Stenosis Demonstrate Adverse Left Ventricular Remodeling and Impaired Cardiac Function Before Surgery With Increased Risk of Postoperative Heart Failure.

Patients With Bicuspid Aortic Stenosis Demonstrate Adverse Left Ventricular Remodeling and Impaired Cardiac Function Before Surgery With Increased Risk of Postoperative Heart Failure.

Journal: Circulation

Published: August 16, 2022

Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.

Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.

Journal: JACC. Heart failure

Published: May 06, 2022

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial.

Journal: American heart journal

Published: January 30, 2022

Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome.

Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome.

Journal: JACC. Heart failure

Published: December 20, 2021

Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.

Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.

Journal: Diabetes research and clinical practice

Published: December 14, 2021

Showing 1-12 of 41

Last Updated: 09/26/2026